On April 6, 2023, P3 Health Partners Inc. closed the transaction. The company has issued 79,912,635 units at a price of $1.1180 per unit for institutional investors, and a purchase price of $1.1938 per unit for employees and consultants for gross proceeds of $89,499,987.10 in the transaction. The transaction included participation from Chicago Pacific Founders Fund, L.P., Chicago Pacific Founders Fund-A, L.P., Chicago Pacific Founders Fund-B, L.P., CPF III PT SPV, LLC, CPF III-A PT SPV, LLC funds managed by Chicago Pacific Founders purchased securities for 63,507,215 units and gross proceeds of $71,000,000, Alyeska Master Fund, L.P., a fund managed by Alyeska Investment Group, L.P. for 4,472,271 units, Leavitt Equity Partners II, L.P., and Leavitt Equity Partners III, L.P., funds mutually managed by Leavitt Equity Partners and Leavitt Partners, Investment Arm for 9,838,997 units, Michael P. Balkin Revocable Trust for 837,661 units, Amir Bacchus for 1,005,193 units and Charlee Co LLC 251,298 units.

The company in aggregate issued 69,157,145 shares of its common stock, warrants to purchase an aggregate of 59,934,479 shares of common stock and pre-funded warrants to purchase an aggregate of 10,755,490 shares of common stock in the transaction.